<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>3(4)</volume><submitter>Mehta A</submitter><pubmed_abstract>Hsp90a's vital role in tumour survival and progression, together with its highly inducible expression profile in gliomas and its absence in normal tissue and cell lines validates it as a therapeutic target for glioma. Hsp90a was downregulated using the post-transcriptional RNAi strategy (sihsp90a) and a post-translational inhibitor, the benzoquinone antibiotic 17-AAG. Glioblastoma U87-MG and normal human astrocyte SVGp12 were treated with sihsp90a, 17-AAG and concurrent sihsp90a/17-AAG (combined treatment). Both Hsp90a gene silencing and the protein inhibitor approaches resulted in a dramatic reduction in cell viability. Results showed that sihsp90a, 17-AAG and a combination of sihsp90a/17-AAG, reduced cell viability by 27%, 75% and 88% (p &lt; 0.001), respectively, after 72 h. hsp90a mRNA co</pubmed_abstract><journal>Cancers</journal><pagination>4228-44</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3763420</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.</pubmed_title><pmcid>PMC3763420</pmcid><pubmed_authors>Shervington L</pubmed_authors><pubmed_authors>Munje C</pubmed_authors><pubmed_authors>Shervington A</pubmed_authors><pubmed_authors>Mehta A</pubmed_authors></additional><is_claimable>false</is_claimable><name>A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.</name><description>Hsp90a's vital role in tumour survival and progression, together with its highly inducible expression profile in gliomas and its absence in normal tissue and cell lines validates it as a therapeutic target for glioma. Hsp90a was downregulated using the post-transcriptional RNAi strategy (sihsp90a) and a post-translational inhibitor, the benzoquinone antibiotic 17-AAG. Glioblastoma U87-MG and normal human astrocyte SVGp12 were treated with sihsp90a, 17-AAG and concurrent sihsp90a/17-AAG (combined treatment). Both Hsp90a gene silencing and the protein inhibitor approaches resulted in a dramatic reduction in cell viability. Results showed that sihsp90a, 17-AAG and a combination of sihsp90a/17-AAG, reduced cell viability by 27%, 75% and 88% (p &lt; 0.001), respectively, after 72 h. hsp90a mRNA co</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011 Dec</publication><modification>2025-04-26T04:11:18.413Z</modification><creation>2020-05-22T16:28:18Z</creation></dates><accession>S-EPMC3763420</accession><cross_references><pubmed>24213135</pubmed><doi>10.3390/cancers3044228</doi></cross_references></HashMap>